BI 2536

For research use only. Not for use in humans.

目录号：S1109

CAS No. 755038-02-9

BI-2536是一种有效的Plk1抑制剂，无细胞试验中IC50为0.83 nM。BI-2536可抑制 Bromodomain 4 (BRD4) ，其Kd值为37 nM，并有效地抑制 c-Myc 的表达。BI-2536可诱导凋亡而减弱自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1978.87	现货
5mg	RMB 981.57	现货
10mg	RMB 1704.35	现货
50mg	RMB 5492.59	现货
100mg	RMB 8160.83	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的BI 2536发表文献168篇：

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Science, 2015, 13;347(6227):aaa2630.

PubMed: 25636800 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 11;147(4):853-67.

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Mol Cell, 2020, 10.1016/j.molcel.2020.01.023

PubMed: 32035037 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6):e201910019

PubMed: 32271878 ( click the link to review the publication )

Cell Rep, 2020, 17;30(11):3605-3615.e5

PubMed: 32187533 ( click the link to review the publication )

Cell Death Differ, 2020, 19

PubMed: 32203171 ( click the link to review the publication )

Oncogene, 2020, 39(15):3145-3162

PubMed: 32060423 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cells, 2020, 9(9)E2126

PubMed: 32961751 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(3):350-362

PubMed: 32017920 ( click the link to review the publication )

ACS Chem Biol, 2020, 20;15(3):669-674

PubMed: 32004428 ( click the link to review the publication )

J Cell Sci, 2020, 2;jcs.244442

PubMed: 32487663 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(4):833-839

PubMed: 31708096 ( click the link to review the publication )

DNA Cell Biol, 2020, 10.1089/dna.2019.5002

PubMed: 32182129 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )
Sci Rep, 2020, 10(1):12327

PubMed: 32704044 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31947732 ( click the link to review the publication )

J Cancer, 2020, 11(11):3274-3287

PubMed: 32231733 ( click the link to review the publication )

Neuroreport, 2020, 31(11):787-797

PubMed: 32568772 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):1824

PubMed: 32645997 ( click the link to review the publication )

Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31511529 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )
EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Elife, 2018, 7:e36739

PubMed: 29897330 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

J Oncol, 2018, 2018:3979527

PubMed: 30631355 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28994651 ( click the link to review the publication )
FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(8):1017-1028

PubMed: 28807782 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Curr Biol, 2017, 27(10):1477-1484

PubMed: 28479321 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28387346 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )
PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )

Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29617-28

PubMed: 26468278 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )
Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(33):34475-93

PubMed: 26439686 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Dev Cell, 2013, 25(6):555-71

PubMed: 23769972 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )
Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

产品安全说明书

PLK抑制剂选择性比较

生物活性

产品描述

特性

BI 2536是第一个有效的Plk1选择性抑制剂，抑制 Plk1的标记。

靶点

c-Myc ^[3] ()	PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)	BRD4 ^[3] (Cell-free assay)
	0.83 nM	3.5 nM	9.0 nM	37 nM(Kd)

体外研究

除了Plk1, BI 2536也抑制 Plk2 和Plk3活性，只是抑制程度低点,IC50分别为3.5 nM和9.0 nM。BI 2536比一组63种其他蛋白激酶（IC50>10 μM）选择性高1000多倍。BI 2536 按10 nM 到 100 nM剂量作用于HeLa细胞，抑制有丝分裂中心体中γ-微管蛋白招募和Apc6 磷酸化，抑制染色体臂中释放黏结蛋白, 诱导产生单极主轴，及一些依赖Plk1的其他有丝分裂过程。与作用于Plk1 RNAi效果相一致, BI 2536处理HeLa细胞，使细胞周期停在G2/M期, 随后DNA分解及凋亡，且累积断裂的PARP p85片段，这种作用存在浓度依赖性。BI 2536抑制一组32种人肿瘤细胞系生长，EC50为2-25 nM,抑制指数生长的hTERT-RPE1,人脐静脉内皮细胞 (HUVECs),和正常大鼠肾脏(NRK) 细胞的增殖，EC50为12-31 nM。^[1] BI 2536 抑制Plk1，降低甲状腺未分化癌(ATC)细胞如 CAL62, OCUT-1, SW1736, 8505C,和 ACT-1 的生长的生长和活力，EC50为1.4-5.6 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	NUS4SYNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfuTWM2OD1yLkCwO\|c3KM7:TR?=	Mo\yV2FPT0WU
ACN	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwMEC4OFMh\|ryP	NVnlWmpzW0GQR1XS
TE-8	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;ITGlEPTB;MD6wNFk1OSEQvF2=	MX;TRW5ITVJ?
LC-2-ad	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrERVZnUUN3ME2wMlAyODl\|IN88US=>	NYnmd3FlW0GQR1XS
ALL-PO	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwMEGzJO69VQ>?	NF3kdGxUSU6JRWK=
EW-16	M{LNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HFdGlEPTB;MD6wNVM{PiEQvF2=	M1L0OHNCVkeHUh?=
KM12	M{DOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTBwMEGzOFgh\|ryP	MkDjV2FPT0WU
GI-1	NWjaVlRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTBwMEGzPFMh\|ryP	NG\wNoJUSU6JRWK=
LS-411N	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTBwMEG0NFch\|ryP	M2fFS3NCVkeHUh?=
ES8	M1LuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXu2[oh4UUN3ME2wMlAyPDl2IN88US=>	MnyzV2FPT0WU
SNU-C2B	NYDsO2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXiO\|M3UUN3ME2wMlAyPTJ4IN88US=>	NGfrWYpUSU6JRWK=
CESS	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkGzTWM2OD1yLkCxOlAzKM7:TR?=	M3fq[XNCVkeHUh?=
697	Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;YU\|JLUUN3ME2wMlAyPjZ6IN88US=>	MYXTRW5ITVJ?
NCI-H1963	NWrJOJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHxTXpKSzVyPUCuNFE3PzNizszN	NYXJcZRbW0GQR1XS
IA-LM	M4q1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoL1TWM2OD1yLkCxOlg5KM7:TR?=	Mo\VV2FPT0WU
SW954	NFv5XmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjrVolRUUN3ME2wMlAyPzB3IN88US=>	NEju[mFUSU6JRWK=
RL95-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\zOG1KSzVyPUCuNFE4OzhizszN	MYLTRW5ITVJ?
LXF-289	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIS2cmdKSzVyPUCuNFE4PyEQvF2=	MnjnV2FPT0WU
OCUB-M	NF;he5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTVTWM2OD1yLkCxPFI3KM7:TR?=	NEfiR4xUSU6JRWK=
RKO	M2TXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjDPFd{UUN3ME2wMlAyQTh5IN88US=>	MX3TRW5ITVJ?
LOUCY	NHXZcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;6[WFpUUN3ME2wMlAzODVizszN	M4LicnNCVkeHUh?=
NOS-1	M3T3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\DNmlEUUN3ME2wMlAzODl\|IN88US=>	NInXNGJUSU6JRWK=
A4-Fuk	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTBwMEKyNVgh\|ryP	NFzZVopUSU6JRWK=
A388	M3e4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4roRmlEPTB;MD6wNlIzPyEQvF2=	NWrRNI5MW0GQR1XS
TE-9	NYPJZ4s3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVm2S3FXUUN3ME2wMlAzOjZzIN88US=>	MWPTRW5ITVJ?
KURAMOCHI	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXmTWM2OD1yLkCyNlg2KM7:TR?=	MX\TRW5ITVJ?
KALS-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPoV\|R{UUN3ME2wMlAzOzN6IN88US=>	NX3SUFhmW0GQR1XS
HOP-62	NEDnSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvaTWM2OD1yLkCyOFIh\|ryP	MY\TRW5ITVJ?
RPMI-8402	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXUZYFKSzVyPUCuNFI2ODhizszN	MUHTRW5ITVJ?
TE-1	NFP5PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XwcGlEPTB;MD6wNlUyOiEQvF2=	MkDCV2FPT0WU
CCRF-CEM	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXCTIxKSzVyPUCuNFI2PDNizszN	NGnOSo9USU6JRWK=
HUTU-80	M3\FfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEe3ZYRKSzVyPUCuNFI3OjRizszN	M{\MVnNCVkeHUh?=
NCI-H1648	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTBwMEK2OFch\|ryP	NWi4Z\|RbW0GQR1XS
HCE-4	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fncWlEPTB;MD6wNlY5OiEQvF2=	MVXTRW5ITVJ?
ETK-1	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTBwMEK3N\|Yh\|ryP	MnLXV2FPT0WU
TE-15	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMEK3N\|gh\|ryP	MoT1V2FPT0WU
BE-13	NW\pN3l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILabWRKSzVyPUCuNFI4PCEQvF2=	MknMV2FPT0WU
KE-37	M{Tn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYO0PFdMUUN3ME2wMlAzPzRzIN88US=>	NYTaNplRW0GQR1XS
NCI-H1355	NFmzXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV31NpExUUN3ME2wMlAzPzh\|IN88US=>	M1GwOXNCVkeHUh?=
TE-11	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3rTWM2OD1yLkCyPFA6KM7:TR?=	MnjyV2FPT0WU
BL-70	NHfJO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYG5UlZOUUN3ME2wMlAzQDV5IN88US=>	M1;hNXNCVkeHUh?=
ES6	M4DpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTnTWM2OD1yLkCyPFgyKM7:TR?=	MnXlV2FPT0WU
GT3TKB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvKTWM2OD1yLkCyPVU{KM7:TR?=	MVLTRW5ITVJ?
LB647-SCLC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{THN2lEPTB;MD6wN\|E6PSEQvF2=	NYnicnJQW0GQR1XS
NB13	M2KzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXy5Z4pCUUN3ME2wMlA{OzF4IN88US=>	MkfZV2FPT0WU
ST486	NHLpbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HXOmlEPTB;MD6wN\|M{PyEQvF2=	M2fWR3NCVkeHUh?=
NCI-H82	NHjPZ\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTBwMEOzOFMh\|ryP	NGXvVlBUSU6JRWK=
NTERA-S-cl-D1	NEW3ZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHxOXZKSzVyPUCuNFM{QTlizszN	M1LIRXNCVkeHUh?=
ES4	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\rTWM2OD1yLkCzOFY{KM7:TR?=	NXnlfZVjW0GQR1XS
SK-NEP-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEe1XoVKSzVyPUCuNFM1QTlizszN	NIfzc4lUSU6JRWK=
Becker	M{[5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVL0bIxDUUN3ME2wMlA{PTV3IN88US=>	NF\tclZUSU6JRWK=
A101D	NXO2em9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TiUWlEPTB;MD6wN\|c1QCEQvF2=	MmWzV2FPT0WU
SK-UT-1	NWDScItMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXvTWM2OD1yLkCzO\|c1KM7:TR?=	NXnkUYx5W0GQR1XS
SW982	NH25cI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHUTWM2OD1yLkCzO\|kh\|ryP	M3PvN3NCVkeHUh?=
TE-10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXLTWM2OD1yLkC0NFQ3KM7:TR?=	NYDCS\|ZUW0GQR1XS
OVCAR-4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\lcoNKSzVyPUCuNFQxPTlizszN	MoC2V2FPT0WU
KP-N-YS	NYS5VmJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPuOZFKSzVyPUCuNFQxQDVizszN	NYLMeFNnW0GQR1XS
BL-41	M1Hzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnM[lFKSzVyPUCuNFQyOjVizszN	NGOyN2tUSU6JRWK=
MZ1-PC	NF7tVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TLemlEPTB;MD6wOFEzPyEQvF2=	M1;EdHNCVkeHUh?=
PF-382	NEnVNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTBwMESxPVgh\|ryP	MWjTRW5ITVJ?
MOLT-13	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXNVoNKSzVyPUCuNFQzOzhizszN	Mkn0V2FPT0WU
HCC1599	M1;rZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[1eXVKSzVyPUCuNFQzPThizszN	MXHTRW5ITVJ?
IST-MEL1	NG\kS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjZeHZKSzVyPUCuNFQ1PDJizszN	MnSyV2FPT0WU
LU-139	M1TGVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVH0R\|Q5UUN3ME2wMlA1PDR{IN88US=>	NGHLUZdUSU6JRWK=
MS-1	NFK4XWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jE[GlEPTB;MD6wOFcxOSEQvF2=	MXXTRW5ITVJ?
MFH-ino	MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMEWwNFMh\|ryP	MYPTRW5ITVJ?
IMR-5	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1X6W2lEPTB;MD6wOVAzOSEQvF2=	MojTV2FPT0WU
TE-5	NV;YS2xRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;yTWM2OD1yLkC1NFY{KM7:TR?=	NX\qRYJTW0GQR1XS
DJM-1	MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvIVW1KSzVyPUCuNFUyPDJizszN	Mn7LV2FPT0WU
NB17	M3XaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nCfWlEPTB;MD6wOVIxPyEQvF2=	M1y4U3NCVkeHUh?=
KARPAS-45	M3;RU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2G4fmlEPTB;MD6wOVM2QCEQvF2=	MYnTRW5ITVJ?
TGBC1TKB	NX3w[mV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G4XmlEPTB;MD6wOVQxPSEQvF2=	MoXkV2FPT0WU
ML-2	NXPoO4MzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHt[4VKSzVyPUCuNFU1OTRizszN	Mlm2V2FPT0WU
no-10	M{DHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLETWM2OD1yLkC1OFc1KM7:TR?=	MWDTRW5ITVJ?
CTV-1	NIDFN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTBwMEW1NFIh\|ryP	M1;tcnNCVkeHUh?=
SJSA-1	M3X3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTBwMEW1NkDPxE1?	NIXtR\|RUSU6JRWK=
HC-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrDW5pKSzVyPUCuNFU2QTdizszN	M{[z[3NCVkeHUh?=
TE-12	NHPjXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm5TWM2OD1yLkC1OlE{KM7:TR?=	NFHze4VUSU6JRWK=
KY821	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDqeY1PUUN3ME2wMlA2PjN{IN88US=>	MnyyV2FPT0WU
TALL-1	NVHHPXBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXrTWM2OD1yLkC1O\|A5KM7:TR?=	NGjPO2hUSU6JRWK=
DEL	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rDdmlEPTB;MD6wOVcxQSEQvF2=	Mm\kV2FPT0WU
TE-6	NIGzc\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jGdWlEPTB;MD6wOVczOiEQvF2=	MnjzV2FPT0WU
SK-LMS-1	NITndm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXtTWM2OD1yLkC1PFA2KM7:TR?=	NUn3ZYY5W0GQR1XS
EW-1	M2DpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTBwMEW4N\|ch\|ryP	NV7DcVF6W0GQR1XS
8-MG-BA	NGfqXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMEW4OVEh\|ryP	MUXTRW5ITVJ?
NALM-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\WTWM2OD1yLkC1PVc{KM7:TR?=	MULTRW5ITVJ?
LB771-HNC	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvvNIZKSzVyPUCuNFU6PzlizszN	M3vWUXNCVkeHUh?=
HT-144	NIS4WmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfUTWM2OD1yLkC2NVMh\|ryP	NXjPSlR2W0GQR1XS
KM-H2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjVTWM2OD1yLkC2NlIyKM7:TR?=	MV\TRW5ITVJ?
SF268	M13H[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Dj[GlEPTB;MD6wOlI5PiEQvF2=	NVG5NJVRW0GQR1XS
RS4-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn24TWM2OD1yLkC2N\|A1KM7:TR?=	Moi4V2FPT0WU
MHH-PREB-1	NF;1cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfQ[FVRUUN3ME2wMlA3OzF7IN88US=>	MUXTRW5ITVJ?
ATN-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzHSotxUUN3ME2wMlA3OzR3IN88US=>	MXPTRW5ITVJ?
BB30-HNC	M{HRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\DWpdKSzVyPUCuNFY1OzZizszN	MYfTRW5ITVJ?
CPC-N	NIHMe3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEiyXFRKSzVyPUCuNFY2OjRizszN	MojpV2FPT0WU
NB1	MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPxT5RKSzVyPUCuNFY3OTNizszN	NET2e4dUSU6JRWK=
KS-1	M4HD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzkTWM2OD1yLkC2O\|Q5KM7:TR?=	Mke3V2FPT0WU
RXF393	NWrwPIVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTBwME[3OlQh\|ryP	M2fMXHNCVkeHUh?=
IST-SL2	NXL6XI5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXOTWM2OD1yLkC3NFA1KM7:TR?=	M4jYZnNCVkeHUh?=
GI-ME-N	NWjyTlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLlS5o2UUN3ME2wMlA4Ojh4IN88US=>	MWjTRW5ITVJ?
VA-ES-BJ	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfwPI9KSzVyPUCuNFc1PzVizszN	MljRV2FPT0WU
NCI-H1581	NH\rb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXOeXdKSzVyPUCuNFc1PzhizszN	M{HuU3NCVkeHUh?=
U-266	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTBwMEe0PVch\|ryP	MnzwV2FPT0WU
DMS-114	NXfGd4FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUeyU3Q2UUN3ME2wMlA4PTJ6IN88US=>	MWjTRW5ITVJ?
NCI-H187	M{nrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUf0RoNNUUN3ME2wMlA4PzJ4IN88US=>	MnziV2FPT0WU
SW962	M2n6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DQcmlEPTB;MD6wO\|g{QSEQvF2=	M4nsfHNCVkeHUh?=
MONO-MAC-6	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwMEe5PFYh\|ryP	NFP3boRUSU6JRWK=
MOLT-16	NGfh[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXy5XHA5UUN3ME2wMlA5OTJzIN88US=>	MWnTRW5ITVJ?
KNS-42	NYmwTJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3aZlZVUUN3ME2wMlA5OTZzIN88US=>	MkD2V2FPT0WU
CMK	M17Xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3f4WWlEPTB;MD6wPFIzPSEQvF2=	NXjJbIdoW0GQR1XS
Ramos-2G6-4C10	NWfZS\|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXJcWU{UUN3ME2wMlA5OjJ3IN88US=>	MXzTRW5ITVJ?
Daudi	NEHsd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\KXFBkUUN3ME2wMlA5OjV4IN88US=>	NF3EOYxUSU6JRWK=
NCI-H510A	NX3vUmdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfsbYVKSzVyPUCuNFg{OzZizszN	MXHTRW5ITVJ?
LB831-BLC	Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvsb4xKSzVyPUCuNFg2PjFizszN	MUPTRW5ITVJ?
HEL	M13Vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvoVpNWUUN3ME2wMlA5PjZ6IN88US=>	NUGzdpBuW0GQR1XS
LU-134-A	NYfG[\|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17xVWlEPTB;MD6wPFcxQCEQvF2=	NH;WWG5USU6JRWK=
NCI-H1694	NED0U5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmW3TWM2OD1yLkC4O\|Q1KM7:TR?=	MXfTRW5ITVJ?
KGN	M1fQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwMEi3OVkh\|ryP	NGfwfXJUSU6JRWK=
A253	NXzyNIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwMEi4NlIh\|ryP	MVXTRW5ITVJ?
DG-75	M3i2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTpTWM2OD1yLkC4PVIzKM7:TR?=	MYLTRW5ITVJ?
MOLT-4	M3fxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfNTWM2OD1yLkC4PVg{KM7:TR?=	MkHxV2FPT0WU
NCI-SNU-5	NXLPcFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjBTWM2OD1yLkC5NlU5KM7:TR?=	MYPTRW5ITVJ?
ONS-76	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHBTWM2OD1yLkC5Nlc3KM7:TR?=	NEDMUIdUSU6JRWK=
NCI-H446	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v1SWlEPTB;MD6wPVQ3OiEQvF2=	M1TKcnNCVkeHUh?=
COR-L279	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvwTWM2OD1yLkC5OVU3KM7:TR?=	M3uzNHNCVkeHUh?=
Calu-6	MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTMdYFZUUN3ME2wMlA6PTl6IN88US=>	MVHTRW5ITVJ?
BC-3	NGHkV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{C2e2lEPTB;MD6wPVY3OiEQvF2=	NEHBZmZUSU6JRWK=
NCI-H2126	M332WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH3dItrUUN3ME2wMlA6PzlzIN88US=>	NXfDfJJrW0GQR1XS
NCI-H1882	M{XzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXJUpliUUN3ME2wMlA6QDB7IN88US=>	NUHXOYdjW0GQR1XS
BB65-RCC	M3zmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTBwMUCyPVQh\|ryP	NVjWZ\|VlW0GQR1XS
DU-4475	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPNOYZKSzVyPUCuNVA1ODdizszN	NHLneoZUSU6JRWK=
NCI-H526	NIP4dZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPodpVKSzVyPUCuNVA1PCEQvF2=	NYWx[VNTW0GQR1XS
NEC8	NEDC[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HpSmlEPTB;MD6xNFUzPSEQvF2=	NWO5TmNGW0GQR1XS
NCI-H1304	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHMSZR{UUN3ME2wMlExPTl2IN88US=>	M{PJS3NCVkeHUh?=
L-540	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHkUHJKSzVyPUCuNVA4ODhizszN	MWnTRW5ITVJ?
NCI-SNU-16	NEj4[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTBwMUC3OFIh\|ryP	MVnTRW5ITVJ?
HD-MY-Z	M2faWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTBwMUC4OVYh\|ryP	NWj1fJZpW0GQR1XS
K-562	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTsb\|NKSzVyPUCuNVA5PThizszN	NGXETlhUSU6JRWK=
JAR	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTBwMUC5NlUh\|ryP	NHzv[llUSU6JRWK=
MZ2-MEL	NWi3TGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXNTWM2OD1yLkGxNFUh\|ryP	Ml6zV2FPT0WU
L-363	NIPURmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnoTWM2OD1yLkGxNFc6KM7:TR?=	NHvZUWxUSU6JRWK=
BV-173	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwMUGyOFMh\|ryP	M{PzUHNCVkeHUh?=
NCI-H524	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDhOZpvUUN3ME2wMlEyOjd2IN88US=>	NI[zOGNUSU6JRWK=
EoL-1-cell	NVvQSWpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHNTWM2OD1yLkGxOlczKM7:TR?=	NHvvXlZUSU6JRWK=
K052	NULCdGp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHBNpRVUUN3ME2wMlEyPzF{IN88US=>	MV3TRW5ITVJ?
TK10	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3qTWM2OD1yLkGxO\|I5KM7:TR?=	M{\KNXNCVkeHUh?=
KU812	NEHmd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo[yTWM2OD1yLkGyNFQ1KM7:TR?=	M4TWRXNCVkeHUh?=
RPMI-8226	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwMUKwOVIh\|ryP	M1nE[3NCVkeHUh?=
MZ7-mel	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTBwMUKyN\|ch\|ryP	NGTkcHhUSU6JRWK=
SK-PN-DW	NX;6U\|BCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\Xe4xKSzVyPUCuNVIzQDdizszN	MonQV2FPT0WU
SR	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHexdGJKSzVyPUCuNVI1PDFizszN	NFrDVolUSU6JRWK=
RPMI-6666	NHzsVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn0TWM2OD1yLkGyO\|Q{KM7:TR?=	NFf1WXFUSU6JRWK=
no-11	NF21VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHBS4lKSzVyPUCuNVI5PjlizszN	M1;Kb3NCVkeHUh?=
EW-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwMUK4PVMh\|ryP	M2rVNXNCVkeHUh?=
LAMA-84	NGnnSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTBwMUOxPFch\|ryP	NV3RbY1oW0GQR1XS
HT	NFXLNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPV[FdKSzVyPUCuNVM2PzRizszN	NVL0e4hWW0GQR1XS
KP-N-RT-BM-1	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXPTWM2OD1yLkGzOlEzKM7:TR?=	NF3IZm9USU6JRWK=
NCI-H747	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLNVJZKSzVyPUCuNVM4KM7:TR?=	NYTBOGdCW0GQR1XS
NCCIT	NX7YfZBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3i3ZmlEPTB;MD6xN\|k{QSEQvF2=	MmPQV2FPT0WU
MLMA	NF\xeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrTVJVKSzVyPUCuNVQyPjdizszN	NWT6VWZSW0GQR1XS
LP-1	M3jMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17yUmlEPTB;MD6xOFI1KM7:TR?=	MV7TRW5ITVJ?
CAL-148	M2jseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnu2TWM2OD1yLkG0OFg{KM7:TR?=	NEP2eotUSU6JRWK=
GB-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\NUmlEPTB;MD6xOFUzPiEQvF2=	NEfve5RUSU6JRWK=
COR-L88	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33TcWlEPTB;MD6xOFgxOiEQvF2=	NETzRmlUSU6JRWK=
NKM-1	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHkTWM2OD1yLkG0PVA3KM7:TR?=	NGXOSY9USU6JRWK=
NB5	M3LIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TINWlEPTB;MD6xOVQ3OiEQvF2=	NHvSR\|NUSU6JRWK=
SH-4	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFuzSGNKSzVyPUCuNVU1PjZizszN	MX\TRW5ITVJ?
EM-2	NIDiPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnMUnBKSzVyPUCuNVU1PjdizszN	MojhV2FPT0WU
TGBC24TKB	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3q1eWlEPTB;MD6xOVY2QSEQvF2=	NH\NUlhUSU6JRWK=
SCLC-21H	MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV75VHg3UUN3ME2wMlE2PzB{IN88US=>	MXvTRW5ITVJ?
COLO-684	NXyzSFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17hS2lEPTB;MD6xOVczOSEQvF2=	Mn7EV2FPT0WU
KINGS-1	Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwMUW5NUDPxE1?	MUfTRW5ITVJ?
LS-123	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYftR2szUUN3ME2wMlE2QTF5IN88US=>	NEHGZ3BUSU6JRWK=
MC116	MnX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\HUWlEPTB;MD6xOlE2QCEQvF2=	M2XjTXNCVkeHUh?=
SU-DHL-1	NIPSTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDpUpJEUUN3ME2wMlE3OjB4IN88US=>	MoDJV2FPT0WU
NCI-H64	NG\ZWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTBwMU[zOFch\|ryP	NH3HbHBUSU6JRWK=
HCE-T	NYXO[4N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\LSmlEPTB;MD6xOlUxPCEQvF2=	Mn\LV2FPT0WU
LOXIMVI	NGHucFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILwSG5KSzVyPUCuNVY6PDlizszN	NEj2PGRUSU6JRWK=
ARH-77	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlftTWM2OD1yLkG3N\|c6KM7:TR?=	Mm\QV2FPT0WU
DOHH-2	M4C0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTBwMUe2O\|Ih\|ryP	Ml\vV2FPT0WU
COLO-320-HSR	M2TEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jFRmlEPTB;MD6xPFE2PCEQvF2=	NUXa[pFYW0GQR1XS
NB6	NYPmfYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTBwMUi1OlYh\|ryP	MlvYV2FPT0WU
L-428	M4TrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3NTWM2OD1yLkG4PFE{KM7:TR?=	Moj4V2FPT0WU
SNB75	M{fmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwMUi4NlQh\|ryP	NV;BZXdJW0GQR1XS
NCI-H2141	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37jS2lEPTB;MD6xPVAyOSEQvF2=	NWPYPFBFW0GQR1XS
KARPAS-299	NWHDenVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIX2NG1KSzVyPUCuNVkzPDFizszN	MVnTRW5ITVJ?
LC4-1	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;XTWM2OD1yLkG5OVAzKM7:TR?=	NEPCcXNUSU6JRWK=
UACC-257	M4f5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTBwMUm5OFch\|ryP	NGLlU\|RUSU6JRWK=
EVSA-T	NUDHTWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;kdI1KSzVyPUCuNlA{OTJizszN	NYfuNJBvW0GQR1XS
JiyoyeP-2003	NWD0OmlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnW[2ZjUUN3ME2wMlIxPDd5IN88US=>	MYnTRW5ITVJ?
NCI-H720	NHvkcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Lq[WlEPTB;MD6yNFUzPSEQvF2=	Ml3KV2FPT0WU
GAK	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nXdWlEPTB;MD6yNVE5QSEQvF2=	MYrTRW5ITVJ?
HH	M4nPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\sdmlDUUN3ME2wMlIyPDB3IN88US=>	NFvHU2tUSU6JRWK=
NCI-H1436	NFe1dlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13jTWlEPTB;MD6yNVQ3PCEQvF2=	NXPGWlEzW0GQR1XS
GR-ST	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLPWGFpUUN3ME2wMlIyPDh6IN88US=>	MkLLV2FPT0WU
BC-1	M3nLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELLd5pKSzVyPUCuNlI3OTZizszN	NEnBd5BUSU6JRWK=
SIG-M5	NYLQSY5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfjTWM2OD1yLkKyO\|I4KM7:TR?=	M{TiV3NCVkeHUh?=
NCI-H345	NGO2SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXxepg5UUN3ME2wMlI{QDB3IN88US=>	MkH5V2FPT0WU
OPM-2	NV7YOXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGC0bWJKSzVyPUCuNlM5QDJizszN	NF7jVIRUSU6JRWK=
LB1047-RCC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnuTWM2OD1yLkK0OFEh\|ryP	M{PKNHNCVkeHUh?=
CTB-1	NUTtRYt{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTPc5FKSzVyPUCuNlQ1QTNizszN	NFjkSndUSU6JRWK=
A3-KAW	M1XWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\CTWM2OD1yLkK1N\|QyKM7:TR?=	MUXTRW5ITVJ?
SF126	NEjOPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XyfWlEPTB;MD6yOVM5OyEQvF2=	NVvPNGNSW0GQR1XS
KARPAS-422	MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjoWmZKSzVyPUCuNlU1OzVizszN	MmTEV2FPT0WU
MEG-01	M{\2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjTcnlKSzVyPUCuNlU3PzNizszN	NF;mWlhUSU6JRWK=
NCI-H209	M{\F[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTYbo1wUUN3ME2wMlI3Ozd2IN88US=>	M1\MZ3NCVkeHUh?=
SBC-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTBwMk[1JO69VQ>?	NGHxZ4lUSU6JRWK=
K5	NIrtS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHl[GpSUUN3ME2wMlI3QTh2IN88US=>	MULTRW5ITVJ?
QIMR-WIL	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17hcmlEPTB;MD6yO\|E2PSEQvF2=	MmXUV2FPT0WU
NMC-G1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTBwMkiyNVch\|ryP	M4qyU3NCVkeHUh?=
IST-MES1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwMkmyN\|gh\|ryP	M1H5XXNCVkeHUh?=
SW684	NWrlTphNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rEWWlEPTB;MD6zNFA1PyEQvF2=	MoLCV2FPT0WU
MV-4-11	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;w[WlEPTB;MD6zNFc5QCEQvF2=	NEL4XIxUSU6JRWK=
LAN-6	M3nGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDKTWM2OD1yLkOxOVczKM7:TR?=	NWLQdmtKW0GQR1XS
RH-1	NGLkb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jDb2lEPTB;MD6zNVg4OSEQvF2=	NX3XcoExW0GQR1XS
CP66-MEL	M2PCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7XSGcyUUN3ME2wMlMyQDd6IN88US=>	NEHDUIZUSU6JRWK=
EC-GI-10	M{e3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIn3ToJKSzVyPUCuN\|I6QDdizszN	M130fnNCVkeHUh?=
GDM-1	NW\USYlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LhW2lEPTB;MD6zN\|A2QSEQvF2=	Ml7FV2FPT0WU
IST-SL1	NWLkXpN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwM{S5NVQh\|ryP	NX;KT4R[W0GQR1XS
KMOE-2	NGqzSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH34NnFKSzVyPUCuN\|UyPzVizszN	NFyxZ49USU6JRWK=
OS-RC-2	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;qTWM2OD1yLkO1OVQ1KM7:TR?=	MkXWV2FPT0WU
HDLM-2	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmG0TWM2OD1yLkO3PFE1KM7:TR?=	MljNV2FPT0WU
DSH1	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXw[IJYUUN3ME2wMlM5PjNzIN88US=>	NF7xVGxUSU6JRWK=
LS-1034	NGXsZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\RTWM2OD1yLkO4PVU1KM7:TR?=	NYDOV2RiW0GQR1XS
LB373-MEL-D	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\XbJl4UUN3ME2wMlM6OTl5IN88US=>	MY\TRW5ITVJ?
GOTO	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjUTWM2OD1yLkSyNVE5KM7:TR?=	M2\Hd3NCVkeHUh?=
MRK-nu-1	NXPuU4h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorDTWM2OD1yLkSyNlA2KM7:TR?=	MW\TRW5ITVJ?
SK-MM-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnsTWM2OD1yLkSzOFQzKM7:TR?=	NGXuXmVUSU6JRWK=
BOKU	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jkeWlEPTB;MD60N\|c6OiEQvF2=	MYHTRW5ITVJ?
NOMO-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjkSnBKSzVyPUCuOFM5PiEQvF2=	NVHxXmpbW0GQR1XS
J-RT3-T3-5	M3jRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7zW3hMUUN3ME2wMlQ1QDd6IN88US=>	NVnsXGk5W0GQR1XS
COLO-668	NYDZTY1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXQeoNIUUN3ME2wMlQ2PjZ6IN88US=>	MVLTRW5ITVJ?
SF539	NGPiWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTBwNEi2PFQh\|ryP	MWnTRW5ITVJ?
LB2518-MEL	M2i0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PofGlEPTB;MD60PVcxOyEQvF2=	NGLzSGZUSU6JRWK=
TE-441-T	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3E[2VKSzVyPUCuOVAyOiEQvF2=	NFX4UJVUSU6JRWK=
MDA-MB-134-VI	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrYTWM2OD1yLkWwPVIyKM7:TR?=	MXPTRW5ITVJ?
SCC-3	NYD5fIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jVTGlEPTB;MD61NVg4OyEQvF2=	MlPJV2FPT0WU
KLE	NEPhSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITVe5NKSzVyPUCuOVIyPzFizszN	NGL5OpFUSU6JRWK=
LB2241-RCC	NHrxV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHvV3VzUUN3ME2wMlUzPTJ3IN88US=>	NVzsPXdsW0GQR1XS
NCI-H1417	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDPcFlKSzVyPUCuOVM1OzVizszN	NEC3XIFUSU6JRWK=
NCI-H2081	NInscG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrxcY1KSzVyPUCuOVg3OTFizszN	M2ezNHNCVkeHUh?=
NCI-H1522	MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37XVWlEPTB;MD61PVM5OyEQvF2=	MWrTRW5ITVJ?
NCI-H889	NGDoeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwNUm4OFQh\|ryP	NFuwWpRUSU6JRWK=
CGTH-W-1	M2rRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPuTWM2OD1yLk[wO\|U2KM7:TR?=	M{XPZ3NCVkeHUh?=
EB-3	Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LWTWlEPTB;MD62NVE2OyEQvF2=	MmO5V2FPT0WU
D-336MG	Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwNkG3PVEh\|ryP	NWS2OWY5W0GQR1XS
LC-1F	NI\4[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnR[JNKSzVyPUCuOlI2QTJizszN	MVfTRW5ITVJ?
MHH-NB-11	NGr5[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHqTWM2OD1yLk[zPFAyKM7:TR?=	M4rUZnNCVkeHUh?=
SK-N-FI	NHvjSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PKVGlEPTB;MD62N\|kyKM7:TR?=	MY\TRW5ITVJ?
NCI-H69	M{HCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDNTWM2OD1yLk[0PFc6KM7:TR?=	NU\JcG86W0GQR1XS
SCH	NGC1coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDsN\|VKSzVyPUCuOlYxOjNizszN	M4nUNHNCVkeHUh?=
LS-513	M2Pidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzVfXlKSzVyPUCuOlczPTlizszN	M{jQWnNCVkeHUh?=
CP67-MEL	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTaTWM2OD1yLk[3OVk3KM7:TR?=	MVXTRW5ITVJ?
GCIY	NHHPNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HkO2lEPTB;MD63NFM3OyEQvF2=	MWfTRW5ITVJ?
SHP-77	NUfNemFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrrfnlQUUN3ME2wMlcxPzN2IN88US=>	NWXNWJB[W0GQR1XS
EHEB	MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTBwN{G4OVQh\|ryP	NHPFTXJUSU6JRWK=
D-247MG	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3vXGNNUUN3ME2wMlc{OjN{IN88US=>	MmryV2FPT0WU
Raji	M3PHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTBwN{S5PFkh\|ryP	NGHObYJUSU6JRWK=
MPP-89	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3S4dGlEPTB;MD63OVk4QCEQvF2=	MmKyV2FPT0WU
EKVX	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXmOG9KSzVyPUCuO\|kxPzNizszN	NXHqUIluW0GQR1XS
HCC2218	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkn3TWM2OD1yLke5NVMyKM7:TR?=	MXTTRW5ITVJ?
KNS-81-FD	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;YUWlEPTB;MD64NVAyOSEQvF2=	NVTRSo06W0GQR1XS
HCC2157	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTBwOES5OVEh\|ryP	MmnVV2FPT0WU
BT-474	M{DocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfCS5N3UUN3ME2wMlg5QDV2IN88US=>	MnvBV2FPT0WU
NCI-H748	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rMTmlEPTB;MD65NVIh\|ryP	M4HneXNCVkeHUh?=
EW-24	NHHWVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwOUKwNFIh\|ryP	MYrTRW5ITVJ?
D-263MG	M37MUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPpN4dvUUN3ME2wMlk1PTF{IN88US=>	NFnK[GRUSU6JRWK=
OMC-1	M1juSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7xRVVEUUN3ME2wMlk3Ozd\|IN88US=>	Mn7rV2FPT0WU
NCI-H2196	NIX1d4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTBwOUe3O\|ch\|ryP	NYnSNG5uW0GQR1XS
HAL-01	NHHjN\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M124PWlEPTB;MD65PVg4OiEQvF2=	NX;p[WhIW0GQR1XS
NCI-H2107	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PM[mlEPTB;MT6wNVg2PCEQvF2=	NHLSSY1USU6JRWK=
LB996-RCC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPOZoRqUUN3ME2xMlA5ODVzIN88US=>	MmfJV2FPT0WU
NCI-H1395	NYSxbVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTFwMUC2O{DPxE1?	M{DjTXNCVkeHUh?=
CHP-126	NXr4[mVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\reHFOUUN3ME2xMlE3OTl7IN88US=>	MUnTRW5ITVJ?
NB69	MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoGxTWM2OD1zLkK2NVQ5KM7:TR?=	M2TPSnNCVkeHUh?=
CAS-1	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFwM{SyN\|Eh\|ryP	MkDvV2FPT0WU
JVM-3	M3;3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zyPGlEPTB;MT60O\|g2PSEQvF2=	NFXC[INUSU6JRWK=
DMS-153	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfNe29mUUN3ME2xMlU4Pjd2IN88US=>	NV7PdnZSW0GQR1XS
SK-MEL-2	NVHLVm5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;WRWlEPTB;MT63NVc5QSEQvF2=	NUXiUndoW0GQR1XS
NCI-H1155	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTFwN{O2O\|Yh\|ryP	MlnUV2FPT0WU
NCI-H1092	MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTFwN{[xPFIh\|ryP	M4PlN3NCVkeHUh?=
LU-165	NVTYbZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjNTolKSzVyPUGuPFY1PzZizszN	MmCyV2FPT0WU
HL-60	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHju[WVKSzVyPUGuPVk6ODhizszN	MWrTRW5ITVJ?
REH	M{XiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTJwMEC1PFIh\|ryP	MmfoV2FPT0WU
JVM-2	M2XYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIqxTYJKSzVyPUKuNFYyOzVizszN	MX\TRW5ITVJ?
MN-60	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJwMUezNFgh\|ryP	NEPR[JhUSU6JRWK=
SCC-15	NFnEdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHSNmQ6UUN3ME2yMlIxOjdizszN	M3jCWXNCVkeHUh?=
SNU-C1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzYUo5UUUN3ME2yMlIyOzR\|IN88US=>	MX;TRW5ITVJ?
SK-MEL-1	M3vSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHryRYhKSzVyPUKuN\|IxPDdizszN	NXy2fVVSW0GQR1XS
TGW	M17RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULhbG44UUN3ME2yMlM2ODJ5IN88US=>	NIXJPFdUSU6JRWK=
CA46	M3HhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37GZ2lEPTB;Mj63OVk3PyEQvF2=	NXjzTWM6W0GQR1XS
NCI-H23	MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTJwOEC3PVEh\|ryP	NGnObJlUSU6JRWK=
MMAC-SF	M17Jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\pdVZFUUN3ME2yMlg3PjJ6IN88US=>	M1HBNHNCVkeHUh?=
NCI-H2171	M2\SW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTsWWlKSzVyPUOuNFM1PDhizszN	Mlz1V2FPT0WU
A704	M4f5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTNwMUSxPVQh\|ryP	MWTTRW5ITVJ?
DB	NUfqR3p7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\6[GJKSzVyPUOuNlU2PzZizszN	NG[4RVZUSU6JRWK=
NCI-H719	NHPWW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTNwM{CzPFQh\|ryP	NX3GfolKW0GQR1XS
MC-CAR	M1i3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnIZ4x3UUN3ME2zMlU1QDF5IN88US=>	NEHSVmNUSU6JRWK=
SIMA	M1TGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3n1[WlEPTB;Mz61PFQyPiEQvF2=	NWjiOG1TW0GQR1XS
SW872	NVHpbZNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLxR5ZKSzVyPUOuO\|gyODFizszN	MoSwV2FPT0WU
HCC1187	M1PBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3V[3c1UUN3ME2zMlc5OzF3IN88US=>	NXnnbHNEW0GQR1XS
EW-13	NGP1UWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXr4SW1wUUN3ME2zMlg{PDF5IN88US=>	MUXTRW5ITVJ?
NCI-SNU-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TjfGlEPTB;ND6yNVk6QSEQvF2=	MV\TRW5ITVJ?
NCI-H226	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3:yc2lEPTB;ND6zN\|YxPiEQvF2=	MVfTRW5ITVJ?
RPMI-8866	NX3MRVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljmTWM2OD12LkO2NFI6KM7:TR?=	MlGwV2FPT0WU
OCI-AML2	NFjEdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rYNGlEPTB;ND61OVI{KM7:TR?=	MlzhV2FPT0WU
LU-65	M1LFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH5cppuUUN3ME20Mlk{ODN\|IN88US=>	MmS4V2FPT0WU
SK-N-DZ	NIr1TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;GZ4pKSzVyPUWuOlM1PjVizszN	NFrncllUSU6JRWK=
NB14	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTVwOUexN\|Uh\|ryP	NWTubWxRW0GQR1XS
COLO-829	NV[5eJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmezTWM2OD14LkOzN\|U6KM7:TR?=	MVzTRW5ITVJ?
MHH-CALL-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTZwNUG1NFgh\|ryP	MnPpV2FPT0WU
NCI-H1770	M3nYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\oVIk3UUN3ME22MlY3QTB2IN88US=>	Moi4V2FPT0WU
ECC4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTZwOEKxO\|kh\|ryP	MkPhV2FPT0WU
A498	NEnZXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDtfHlbUUN3ME22Mlg4OTl{IN88US=>	NUfDWXJ6W0GQR1XS
DMS-79	NV7XbWJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoexTWM2OD15LkC0OVEzKM7:TR?=	NF3wTVJUSU6JRWK=
P30-OHK	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnsTWM2OD15LkKxPVA3KM7:TR?=	MUjTRW5ITVJ?
D-502MG	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTdwOUizOkDPxE1?	M1nSRXNCVkeHUh?=
RCC10RGB	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRThwME[yPEDPxE1?	MXfTRW5ITVJ?
U-698-M	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nHWmlEPTB;OD6yPVIzPiEQvF2=	Mlu4V2FPT0WU
BB49-HNC	NF\UVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmi1TWM2OD17LkSyNlY2KM7:TR?=	NGPkT49USU6JRWK=
ES1	NHXacnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTkTWM2OD17Lk[4PVU3KM7:TR?=	M2TkUXNCVkeHUh?=
MFM-223	NYW4WmY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn6RndZUUN3ME2xNE46QTJ5IN88US=>	NH;NZWtUSU6JRWK=
C2BBe1	M2i0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlH1TWM2OD1zMT6zOVI{KM7:TR?=	NVvKSm42W0GQR1XS
EB2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjxWGVmUUN3ME2xNk43QDhzIN88US=>	M4T1VHNCVkeHUh?=
C8166	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrpTWM2OD1zMz64N\|A{KM7:TR?=	NFHZ[2VUSU6JRWK=
ES3	M33FeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTF\|Lkm5O\|ch\|ryP	NVH3SmplW0GQR1XS
NCI-H1650	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTF4LkO3OlUh\|ryP	MUXTRW5ITVJ?
Mo-T	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTF5LkSwNlkh\|ryP	MV;TRW5ITVJ?
NB7	NUDnUGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLkTWM2OD1zNz63OFY4KM7:TR?=	MnvEV2FPT0WU
ES7	M1\KdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPydHlKSzVyPUG5MlU2ODdizszN	M{\ucHNCVkeHUh?=
ES5	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2S0UmlEPTB;MkGuO\|Y4OSEQvF2=	M3nnb3NCVkeHUh?=
MSTO-211H	NIC3dI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJzLki4OVgh\|ryP	NXTlO\|dEW0GQR1XS
U-87-MG	NE\kPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3EcpNKSzVyPUK1MlE6PjZizszN	NVvvOVFoW0GQR1XS
THP-1	NXjtfGY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO1TWM2OD1{OT63NlAyKM7:TR?=	NIH3PWVUSU6JRWK=
NB10	NHfKfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTNyLkK2PVQh\|ryP	M1i2T3NCVkeHUh?=
NH-12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTN\|LkKwNVch\|ryP	NV7KflZ7W0GQR1XS
COLO-824	NWLMR\|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTN2LkGwNFYh\|ryP	NXvLdmhmW0GQR1XS
SKM-1	M3nO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;FbFJKSzVyPUO3Mlg1OjJizszN	NUnFelIzW0GQR1XS
NCI-H1838	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{j4ZWlEPTB;M{iuN\|c6PyEQvF2=	M{j5dXNCVkeHUh?=
RL	M2TPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjPOmlyUUN3ME2zPU4zPDd5IN88US=>	NHXwNmxUSU6JRWK=
COLO-800	M3;ocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFmy[FdKSzVyPUSwMlA4PzNizszN	NED4XJJUSU6JRWK=
KG-1	NIruOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TTSmlEPTB;NECuPFk2PSEQvF2=	M{PlZnNCVkeHUh?=
TUR	NV7Ke5A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{f6U2lEPTB;NEGuOlM6QSEQvF2=	MnLPV2FPT0WU
LNCaP-Clone-FGC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17aVWlEPTB;NEGuPVAyPyEQvF2=	M{GxO3NCVkeHUh?=
NCI-H322M	NWjwXWpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTR{LkW5PFQh\|ryP	MVnTRW5ITVJ?
LNCaP	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHqOmxmUUN3ME25NU4{KG6P	NWT6bmFxOjV3MEWxO\|Q>
C4-2	NITz[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1q2eGlEPTB;ODDuUS=>	NXfDXJJkOjV3MEWxO\|Q>
JURKAT	NHHaOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Moj3NlQhcA>?		NVuzWFNMUUN3ME20NVYvPjZibl2=	M{\ETlI1PTF7OUm1
MOLT-4	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVqyOEBp		M1TvNmlEPTB;Mki1N{42KG6P	M4K1blI1PTF7OUm1
REH	M4rmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV6yOEBp		NIS2[FVKSzVyPUK4O{43QCCwTR?=	M{XrW\|I1PTF7OUm1
NALM-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX2yOEBp		NXPyNVlvUUN3ME2zOFM{OCCwTR?=	M3jZS\|I1PTF7OUm1
RS 4;11	NHLIcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFrOcIQzPCCq		NG\XNJBKSzVyPUWxPU4xPSCwTR?=	MYOyOFUyQTl7NR?=
697	NUPJO5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1LPeVI1KGh?		M37SNWlEPTB;MkGwO{4yKG6P	MkPTNlQ2OTl7OUW=
SIL-ALL	NEnINWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH;vRokzPCCq		MmP5TWM2OD1zOUmuO\|chdk1?	MmfmNlQ2OTl7OUW=
CEM	NEOxcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoDjNlQhcA>?		MYrJR\|UxRTV{LkG4JI5O	NXThSlZIOjR3MUm5PVU>
P12	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETubJUzPCCq		NVLtNVJXUUN3ME2zPU4zPyCwTR?=	MnnUNlQ2OTl7OUW=
NALM-16	NEG2ZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFv3fW0zPCCq		MWPJR\|UxRTl4LkK4JI5O	MmHlNlQ2OTl7OUW=
JURKAT	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{\DUVQ5KGh?		NH;wWHRKSzVyPUG0Mlg1KG6P	MnSyNlQ2OTl7OUW=
MOLT-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWC0PEBp		MVzJR\|UxRTJ4Lk[gcm0>	NWHzVW5TOjR3MUm5PVU>
REH	NIfvVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYm0PEBp		M1;q[mlEPTB;NESuO\|Ehdk1?	MmDCNlQ2OTl7OUW=
NALM-6	NVXLfHVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV60PEBp		MmPWTWM2OD1{Mz6yOkBvVQ>?	NV\ZeXRCOjR3MUm5PVU>
RS 4;11	NU\vS4lzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVjiNmpxPDhiaB?=		M3;G[mlEPTB;MU[0MlI5KG6P	MnnlNlQ2OTl7OUW=
697	NFvtXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVi0PEBp		NXrjO45FUUN3ME2zNFUvOyCwTR?=	NYDxWZRtOjR3MUm5PVU>
SIL-ALL	NFSxVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYi0PEBp		MlXMTWM2OD15ND62NkBvVQ>?	NVzLcJo6OjR3MUm5PVU>
CEM	NH64O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPFU5E1QCCq		NHno[YRKSzVyPUK0MlU2KG6P	M2X1ZVI1PTF7OUm1
P12	MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkG4OFghcA>?		NXHLPHNtUUN3ME2xPE41PiCwTR?=	NYjKXodQOjR3MUm5PVU>
NALM-16	NEmzZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIHBemc1QCCq		M336TWlEPTB;NkOuNlQhdk1?	MmXFNlQ2OTl7OUW=
JURKAT	M{\EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYTwW2diPzJiaB?=		MV3JR\|UxRTNwNkWgcm0>	NWfJTZJROjR3MUm5PVU>
MOLT-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYe3NkBp		MYTJR\|UxRTdwM{mgcm0>	MmT0NlQ2OTl7OUW=
REH	NYi3Tpk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mon1O\|IhcA>?		NECxXINKSzVyPUG2MlAyKG6P	NV;LXZkzOjR3MUm5PVU>
NALM-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXy3NkBp		NUTSTWx{UUN3ME2xMlc5KG6P	M4TzOlI1PTF7OUm1
RS 4;11	NYPHUHhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnLkO\|IhcA>?		NUHHS3lsUUN3ME20MlM5KG6P	M2D1VlI1PTF7OUm1
697	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvmO\|IhcA>?		Mlz2TWM2OD15ND6yPEBvVQ>?	NHiyNIozPDVzOUm5OS=>
SIL-ALL	M{HEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2HmV\|czKGh?		NVzTcIhWUUN3ME23MlIhdk1?	NYTJc3pwOjR3MUm5PVU>
CEM	M1vxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIf0cHM4OiCq		MXvJR\|UxRTVwNEKgcm0>	NFj3b3AzPDVzOUm5OS=>
P12	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYG3NkBp		MWjJR\|UxRTZwM{egcm0>	MY[yOFUyQTl7NR?=
NALM-16	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC3NkBp		NVnyS5hRUUN3ME23O{44OyCwTR?=	M2Gyd\|I1PTF7OUm1
Y79	MVLBdI9xfG:\|aYOgRZN{[Xl?	NHflRYwyNTVyIH7N	NWD3OXp2OTJxMkSgbC=>	M3[zOWROW09?	M{\DfIlv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=>	NXi2[\|RnOjR\|Nk[2OlU>
WER-Rb-1	NYjGSHFISXCxcITvd4l{KEG\|c3H5	NX;FW5Y2OS13MDDuUS=>	MmHnNVIwOjRiaB?=	NFjP[4tFVVOR	MkXpbY5lfWOnZDDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IFjU	Mn7RNlQ{PjZ4NkW=
G7	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrSWJpKSzVyPUOuN{BvVQ>?	MV6yOFIxPDd\|Mx?=
G166	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LxeWlEPTB;Nz6wJI5O	MknTNlQzODR5M{O=
CB660	M2r6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTZwNDDuUS=>	NWTrNGVLOjR{MES3N\|M>
CB1117	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTF3Lk[gcm0>	MWGyOFIxPDd\|Mx?=
KB-3-1	M1LLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\iTWM2OD1zLkS4JOKyKDBwNUOgcm0>	MW[yN\|k3OjR2NR?=
KB-8-5-11	M2P0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4W0NmlEPTB;NT6wNUDDuSB{LkCxJI5O	NY\GcVF6OjN7NkK0OFU>
KB-C-1	M1X0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX6zRY5iUUN3ME2xOk44PiEEsTC0MlUyKG6P	M4GzfFI{QTZ{NES1
KB-V-1	M3HjN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXtO3FKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?=	MWmyN\|k3OjR2NR?=
OVCAR-8	NFn4W\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYOwcXdEUUN3ME23MlE6KMLzIEOuOlAhdk1?	Mmf6NlM6PjJ2NEW=
NCI-ADR-RES	NXzxb41lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTF{N{OuN\|AhyrFiMUmxMlIxKG6P	MX6yN\|k3OjR2NR?=
MCF7	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnPVZRKSzVyPUWuNVEhyrFiMT60O{BvVQ>?	M3nCdlI{QTZ{NES1
MCF7-FLV1000	NEP1UnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTN7Mz6xPEDDuSB5ND64N{BvVQ>?	M33wT\|I{QTZ{NES1
S1	M1e2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJ2LkOwJOKyKDRwN{Wgcm0>	NGHGUHUzOzl4MkS0OS=>
S1-M1-80	M3\MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXINGlYUUN3ME2yOlEvODZiwsGgOFgvOjVibl2=	MnzvNlM6PjJ2NEW=
CORL-23/P	NF;UVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPIR2hKSzVyPUSuN\|ghyrFiMT6yOUBvVQ>?	MXKyN\|k3OjR2NR?=
CORL-23/R	M3exO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;uTWM2OD13LkG2JOKyKDFwOEOgcm0>	M4LnTFI{QTZ{NES1
NIH3T3	NEPGSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXH2cVc1UUN3ME20NE43OCEEsTC0Mlk4KG6P	MV6yN\|k3OjR2NR?=
NIH3T3-G185	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjGVY5vUUN3ME2yOFE{NjRyINMxJFQzOy54NjDuUS=>	NVX0U4J2OjN7NkK0OFU>
pcDNA-HEK293	NXLtTYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzT[JdKSzVyPUKuO\|UhyrFiMD62O{BvVQ>?	M{\1UlI{QTZ{NES1
MDR19-HEK293	NGTMVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3YcFZYUUN3ME24OU42OCEEsTCxN{43PyCwTR?=	Mm\5NlM6PjJ2NEW=
R482-HEK293	NYnyXXRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DETGlEPTB;MkWuPVchyrFiND65OUBvVQ>?	NHK4UHMzOzl4MkS0OS=>
MRP1-HEK293	M2OyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXT1TI9iUUN3ME2yMlk6KMLzIEGuOFkhdk1?	M{jZXFI{QTZ{NES1
SF188	NFXqWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH2c5dHOTBvMUCwJI5O	MmH5NlQuQTZiaB?=	NHPZOYtFVVOR	NGLTW2NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	NWH3NVl1OjN6OEe2OFU>
T98G	M2TlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTGR2hbOTBvMUCwJI5O	M3jW[\|I1NTl4IHi=	NH3ZNlNFVVOR	M{T2dYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHPvcoNmdnS{YYTpc44uKGSncHXk[Y51KG2jbn7ldi=>	MW[yN\|g5PzZ2NR?=
DU145	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHu2N4JFVVOR	M1vqb2lEPTEkiMy2NEBvVQ>?	NFPofFAzOzh6NESyPC=>
LNCaP	NYHjVoFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVTVTlFCTE2VTx?=	MkPXTWM2OOLKvEe1JI5O	MX[yN\|g5PDR{OB?=
PC3	NHrjV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{OzeWROW09?	MoH6TWM2OOLKvEG3OUBvVQ>?	MWCyN\|g5PDR{OB?=
RT4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXW0TXpsUUN3ME2yO{4zOSCwTR?=	NFLjN\|MzOzd7Mk[zPS=>
5637	Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PtZWlEPTB;NEWuOFchdk1?	NXjoXoV4OjN5OUK2N\|k>
T24	NGrhVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDMTWM2OD15OT6xNkBvVQ>?	NEG3e3IzOzd7Mk[zPS=>
MCF7	MlzOSpVv[3Srb36gRZN{[Xl?	M2XGWVExOCCwTR?=	MX[xJIg>	M2XkU2ROW09?	M3PP[ZJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ?	MmD5NlM4PzB{NES=
KB-V1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXKdGQ6UUN3ME2zMlkzKM7:TR?=	NFy2OJczOzV7M{G5Oi=>
Hec50co	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[wTWM2OD13IH7N	MUOyN\|E1PjZ6Nx?=
MDA-MB-468	MXLBdI9xfG:\|aYOgRZN{[Xl?	M1LvcFEwPS9zMDDuUS=>	MnPsNlQwPDhxN{KgbC=>	M3ntdGROW09?	MX;pcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MVKyN\|E1PDJ7NB?=
MCF10A	MXXBdI9xfG:\|aYOgRZN{[Xl?	M1PGNFEwPS9zMDDuUS=>	MYWyOE81QC95MjDo	NWj2bVNjTE2VTx?=	MlXvbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M1PlbFI{OTR2Mkm0
Huh-7	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXhNU8yOC9zMECvNVAxOCCwTR?=	M1rqPVQ5KGh?		NEe1O2tl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGSxc3Wt[IVx\W6mZX70cJk>	MUSyNlc1PTV6Nx?=
Daoy	NIjUUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxMlg4PS1{NECgcm0>	NE\ibWg4OiCq	NEDFcZFFVVOR	MUTJR\|UxRTVibl2=	M4HURlIzOzlyMke5
ONS-76	NGnKUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M334W\|EvQDd3LUK0NEBvVQ>?	NGjQT4s4OiCq	M4jlemROW09?	NHL2TWpKSzVyPUeuOUBvVQ>?	NFL1NGMzOjN7MEK3PS=>
SUM 149	M3T3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS0NE0yODBibl2=	NYnjOG5LPzJiaB?=		NWLG[45HcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	MV6yNlMxQTl\|OR?=
MDA-MB-231	NIDmPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zrflAuOTByIH7N	MY[3NkBp		NEXwcnhqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	MWCyNlMxQTl\|OR?=
HR5	NIjNN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGwMVExOCCwTR?=	NXrSSZVsPzJiaB?=		NEOx[FlqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	NHTWeIwzOjNyOUmzPS=>
BT-474-M1	NEnVeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7zNE0yODBibl2=	M4\iNVczKGh?		M372Z4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	M3;Te\|IzOzB7OUO5
AU565	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLBR2szOC1zMECgcm0>	MW[3NkBp		M3HUT4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MWSyNlMxQTl\|OR?=
T47D	NXviOXcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjCOFIyOC1zMECgcm0>	M3XEVVczKGh?		M3;pXIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MorNNlI{ODl7M{m=
MCF7	MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;iNE0yODBibl2=	MUK3NkBp		M{XlZ4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MlPUNlI{ODl7M{m=
HCT116p53(+/+)	MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjsXnEyOC1zMECwJI5O	M2DqN\|I1NzR6IHi=		M4j5bIlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6KGG2IEK1JI5O	M3;u[lIzOjZ{MUex
HCT116p53(-/-)	NGPO[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHQNVAuOTByMDDuUS=>	MmnSNlQwPDhiaB?=		NF\DOVRqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgSCjdDCyOUBvVQ>?	NF62NVQzOjJ4MkG3NS=>
HeLa	NGO1bWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6xNE0yODBibl2=	MVS0PEBp	MXXEUXNQ	MXLJR\|UxRTV{Lkmgcm0>	NYrMV245OjJyOECyN\|U>
HeLa	NVHzNoJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfReWkyOC1zMECgcm0>	NGLZfJk4OiCq	M3PkUWROW09?	NUS3OIJxUUN3ME21NE42KG6P	MWiyNlA5ODJ\|NR?=
GBC	MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XKdVczKGh?		M2jTTGlEPTB;MUSuO\|ghdk1?	NHzDRZkzOTl4NUezPS=>
GB-CL-1	NV;td21nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmfjO\|IhcA>?		NX[5T4h6UUN3ME21MlIzKG6P	M3XoWVIyQTZ3N{O5
Mz-ChA-2	NHnNNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{nyPVczKGh?		MmL0TWM2OD1\|LkOxJI5O	Mmq1NlE6PjV5M{m=
TGBC1-TKB	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnie4FHOTR2IHi=		NIDVSHNKSzVyPU[uO\|Ihdk1?	M2X2ZVIyQTZ3N{O5
Wittier	M{C1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYS4W3lkPzJiaB?=		MlfuTWM2OD1\|LkK2JI5O	MkToNlE6PjV5M{m=
H-1	NEfscppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1;kd\|czKGh?		MWnJR\|UxRTlwNUSgcm0>	NWP1cYxuOjF7NkW3N\|k>
HuH-28	M3LMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnzwO\|IhcA>?		NGX1eVJKSzVyPUGxMlE6KG6P	Mn[0NlE6PjV5M{m=
NEC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEXyPIE4OiCq		MVnJR\|UxRTlwOUigcm0>	MXWyNVk3PTd\|OR?=
REB	M3vTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVjybm1jPzJiaB?=		NYXrc4JDUUN3ME2xN{42OSCwTR?=	Mlv5NlE6PjV5M{m=
CC-LP-1	M{foVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mo\RO\|IhcA>?		NFfPZYFKSzVyPUWuPFQhdk1?	MUmyNVk3PTd\|OR?=
CC-SW-1	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC3NkBp		NIrl[FRKSzVyPUmuOVUhdk1?	MoLvNlE6PjV5M{m=
EGI-1	NXn3Z3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M37uS\|czKGh?		NUTDPGlqUUN3ME2xNE44OiCwTR?=	M1TFV\|IyQTZ3N{O5
Sk-ChA-1	NFjGNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkizO\|IhcA>?		NVvOSGJmUUN3ME2xO{4zKG6P	MmPYNlE6PjV5M{m=
TFK-1	NHviSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnXtO\|IhcA>?		NHH4e49KSzVyPUGzMlQ2KG6P	MkmzNlE6PjV5M{m=
786-O	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHZOU05OCCwTR?=	M2PuVlk3KGh?	M{nnVmhEdA>?	MWrzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	NIPtdJozOTZ2MkO3OC=>
A498	MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPLOU05OCCwTR?=	MYi5OkBp	MVXIR4w>	MWXzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	NUjYOW11OjF4NEKzO\|Q>
ACHN	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nlelUuQDBibl2=	NHXTXpY6PiCq	NGKzPZdJS2x?	NWTybW5Ye3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MXmyNVY1OjN5NB?=
Caki-1	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\OOU05OCCwTR?=	MWC5OkBp	MU\IR4w>	MYTzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	NV7PVoloOjF4NEKzO\|Q>
SN12C	NWPUZY44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELyfm02NThyIH7N	M3z5Vlk3KGh?	NHqwcGtJS2x?	M3XvT5N2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	NH;yWYEzOTZ2MkO3OC=>
HMC-1.1	NX;iZnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULSSndEOS1zMECwJI5O	MorlO\|IhcA>?		MWnpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	M4rtdVIyOjR{MUi5
HMC-1.2	NGfhcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxMVExODBibl2=	MnLpO\|IhcA>?		MXvpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	MljUNlEzPDJzOEm=
C2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTwWnEyOS1zMECwJI5O	NIjaeVM4OiCq		MX;pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	MoGyNlEzPDJzOEm=
CHP-212	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX2O2EyNTF{NTDuUS=>	Mmn5NlQuOTJyIHi=		MV7pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NGTSVJUzOTF4OUK0Ni=>
IMR-32	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zUdlEuOTJ3IH7N	MV2yOE0yOjBiaB?=		MoPhbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	M1;UV\|IyOTZ7MkSy
Kelly	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILFbocyNTF{NTDuUS=>	NVPKXXV5OjRvMUKwJIg>		NVvVcnJKcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	NH\DSIkzOTF4OUK0Ni=>
SH-EP	NFvBe\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nZZVEuOTJ3IH7N	M1PiOVI1NTF{MDDo		NWDFXpdocW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	M3;RPFIyOTZ7MkSy
SH-SY5Y	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYOxMVEzPSCwTR?=	NILaeIwzPC1zMkCgbC=>		NVL0VlExcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	MWOyNVE3QTJ2Mh?=
SK-N-AS	NWjme21PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HZPFEuOTJ3IH7N	M2jjRlI1NTF{MDDo		MkO1bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NGnuN3EzOTF4OUK0Ni=>
SK-N-BE	NYi2cmFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVWxMVEzPSCwTR?=	MV[yOE0yOjBiaB?=		NG\zeGZqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	Mn3oNlEyPjl{NEK=
KG1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLqNU8yOC9zMECgcm0>	MkDGO\|IhcA>?	MX3EUXNQ	M3fhfIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	MnXzNVk1PTh\|NUi=
U937	NEK5UlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3WNU8yOC9zMECgcm0>	M4XPSVczKGh?	NWTqcIt5TE2VTx?=	Mn25bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NYDySpc2OTl2NUizOVg>
CAL62	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLKSYM{OC5zLUGwNEBvVQ>?	NG\5OYw4OiCq	NFjWNZpFVVOR	NUmwOIdPTUN3ME2xMlQhdk1?	M3LQclE6OjJ\|NUWz
OCUT-1	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmwMlEuOTByIH7N	NXf1O5pIPzJiaB?=	M4G5V2ROW09?	MkSzSWM2OD1{LkOgcm0>	NIXhfG4yQTJ{M{W1Ny=>
8505C	NIXpO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1n6RlAvOS1zMECgcm0>	MWq3NkBp	NXztUJRnTE2VTx?=	M2HvdGVEPTB;Mz6yJI5O	M3u4NVE6OjJ\|NUWz
ACT-1	NFzWfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPm[ooyOC5zLUGwNEBvVQ>?	MVq3NkBp	M3e4bGROW09?	NIi4NIdGSzVyPUWuOEBvVQ>?	M4PIdFE6OjJ\|NUWz
SW1736	M1rNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LBOFAvOS1zMECgcm0>	M3zVSFczKGh?	M2TiXWROW09?	M33qdWVEPTB;NT62JI5O	NWW3cm5{OTl{MkO1OVM>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

体内研究

BI 2536静脉注射给药多种移植瘤模型，每周一次或两次，效果都很好，通过使细胞周期停滞而抑制细胞增殖，随后诱导肿瘤细胞死亡。BI 2536按 50 mg/kg剂量处理HCT 116移植瘤，每周一次或两次，显著抑制肿瘤生长，T/C 分别为15%和0.3%。BI 2536每周处理两次BxPC-3和A549模型，也显著抑制肿瘤生长，T/C分别为5% 和14%。^[1]

激酶实验： ^[1]	- 合并体外Plk1激酶实验: 重组人Plk1 (1-603残基) 作为氮端，携带杆状病毒表达系统的GST-标记的融合蛋白通过亲和层析，使用谷胱甘肽-琼脂糖而纯化。在梯度稀释的BI 2536存在时，使用 20 ng 重组激酶，及10 μg牛奶中的酪蛋白作为底物进行Plk1 酶活性实验。在终体积为60 μL 的混合物(15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP)中30^oC下进行激酶反应45分钟。加入 125 μL 冰冻的5% TCA终止反应。沉淀物转移到混合酯纤维素的多屏过滤板上，使用1% TCA冲洗实验板，然后利用放射性进行测量。绘制剂量反应曲线，而计算IC50值。
细胞实验： ^[1]	- 合并 Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji, PC-3,等等 Concentrations: 溶于DMSO, 终浓度为~1 μM Incubation Time: 24,和72小时 Method: 使用不同浓度BI 2536处理细胞24和72小时。在荧光分光光度计中测量Alamar Blue染料转换而测定细胞生长。为了测定培养基中DNA含量，细胞悬液在80%乙醇中混合, 使用溶于PBS的0.25% Triton X-100处理5分钟，然后与0.1% RNase 和溶于PBS的 10 μg/mL碘化丙啶在室温下温育20分钟。通过流式细胞仪分析而测定细胞周期谱。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 皮下注射HCT 116, NCI-H460, 或A549 细胞的雌性BomTac:NMRI-Foxn1nu 小鼠 Dosages: ~50 mg/kg Administration: 静脉注射，每周一到两次 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
	Ethanol	'100 mg/mL
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG 400+0.5% Tween 80+5% Propylene glycol	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download BI 2536 SDF

分子量	521.66
化学式	C₂₈H₃₉N₇O₃
CAS号	755038-02-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
回答：
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

选择性强的Plk抑制剂

GSK461364 : Plk1-selective, K_i=2.2 nM.
用于临床的Plk抑制剂

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
最新的Plk抑制剂

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
经典的Plk抑制剂

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

研究领域

产品类型

定制您的化合物库

BI 2536

客户使用Selleck生产的BI 2536发表文献168篇：

产品安全说明书

PLK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download BI 2536 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技术支持

常见问题及建议解决方法

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

相关PLK产品